Neurodegeneration and neuroprotection in Parkinson's disease:
Parkinson's disease (PD) is an age-related neurodegenerative disorder characterized by a relatively selective degeneration of dopaminergic neurons, a loss of striatal dopamine, and intracellular inclusions. Current treatment consists of a dopamine replacement strategy, primarily using the dopam...
Gespeichert in:
Format: | Buch |
---|---|
Sprache: | English |
Veröffentlicht: |
London [u.a.]
Acad. Press
1996
|
Schriftenreihe: | Neuroscience perspectives
|
Schlagworte: | |
Zusammenfassung: | Parkinson's disease (PD) is an age-related neurodegenerative disorder characterized by a relatively selective degeneration of dopaminergic neurons, a loss of striatal dopamine, and intracellular inclusions. Current treatment consists of a dopamine replacement strategy, primarily using the dopamine precursor levodopa. However the majority of patients experience intolerable drug-related side effects, an unacceptable level of disability, and an increased mortality rate. Accordingly, there has been intense interest in the development of a 'neuroprotective therapy' that can prevent neuronal degeneration and slow or stop disease progression. It is likely that a cascade of events involving free radicals and oxidative stress, mitochondrial dysfunction with a bioenergetic impairment, excitotoxicity, and a rise in intracytoplasmic free calcium with activation of biodestructive enzymes contributes to the neurodegenerative process There is also interest in the role of apoptotic cell death in neurodegeneration and the possibility that some small molecules can provide neuroprotection or neuronal rescue by upregulating cellular defenses through the induction of translational changes and new protein synthesis. This is the first book to comprehensive review the factors implicated in the pathogenesis of cell death in PD. Each chapter of this book examines a different factor and considers the evidence supporting its participation in the neurodegenerative process and specific strategies based on this mechanism that might lead to neuroprotection |
Beschreibung: | XII, 224 S. Ill., graph. Darst. |
ISBN: | 0125254458 |
Internformat
MARC
LEADER | 00000nam a2200000 c 4500 | ||
---|---|---|---|
001 | BV010984674 | ||
003 | DE-604 | ||
005 | 20010108 | ||
007 | t| | ||
008 | 961002s1996 xx ad|| |||| 00||| eng d | ||
020 | |a 0125254458 |9 0-12-525445-8 | ||
035 | |a (OCoLC)35019408 | ||
035 | |a (DE-599)BVBBV010984674 | ||
040 | |a DE-604 |b ger |e rakwb | ||
041 | 0 | |a eng | |
049 | |a DE-20 |a DE-355 |a DE-578 | ||
050 | 0 | |a RC382 | |
082 | 0 | |a 616.833 |2 20 | |
084 | |a YG 5500 |0 (DE-625)153506:12905 |2 rvk | ||
245 | 1 | 0 | |a Neurodegeneration and neuroprotection in Parkinson's disease |c ed. by C. W. Olanow ... |
264 | 1 | |a London [u.a.] |b Acad. Press |c 1996 | |
300 | |a XII, 224 S. |b Ill., graph. Darst. | ||
336 | |b txt |2 rdacontent | ||
337 | |b n |2 rdamedia | ||
338 | |b nc |2 rdacarrier | ||
490 | 0 | |a Neuroscience perspectives | |
520 | 3 | |a Parkinson's disease (PD) is an age-related neurodegenerative disorder characterized by a relatively selective degeneration of dopaminergic neurons, a loss of striatal dopamine, and intracellular inclusions. Current treatment consists of a dopamine replacement strategy, primarily using the dopamine precursor levodopa. However the majority of patients experience intolerable drug-related side effects, an unacceptable level of disability, and an increased mortality rate. Accordingly, there has been intense interest in the development of a 'neuroprotective therapy' that can prevent neuronal degeneration and slow or stop disease progression. It is likely that a cascade of events involving free radicals and oxidative stress, mitochondrial dysfunction with a bioenergetic impairment, excitotoxicity, and a rise in intracytoplasmic free calcium with activation of biodestructive enzymes contributes to the neurodegenerative process | |
520 | |a There is also interest in the role of apoptotic cell death in neurodegeneration and the possibility that some small molecules can provide neuroprotection or neuronal rescue by upregulating cellular defenses through the induction of translational changes and new protein synthesis. This is the first book to comprehensive review the factors implicated in the pathogenesis of cell death in PD. Each chapter of this book examines a different factor and considers the evidence supporting its participation in the neurodegenerative process and specific strategies based on this mechanism that might lead to neuroprotection | ||
650 | 7 | |a Zenuwstelselaandoeningen |2 gtt | |
650 | 7 | |a Ziekte van Parkinson |2 gtt | |
650 | 4 | |a Cell Death |x physiology | |
650 | 4 | |a Nerve Degeneration |x physiopathology | |
650 | 4 | |a Nervous system |x Degeneration | |
650 | 4 | |a Oxidative Stress |x physiology | |
650 | 4 | |a Parkinson Disease |x drug therapy | |
650 | 4 | |a Parkinson Disease |x physiopathology | |
650 | 4 | |a Parkinson's disease | |
650 | 0 | 7 | |a Parkinson-Krankheit |0 (DE-588)4044683-9 |2 gnd |9 rswk-swf |
650 | 0 | 7 | |a Nervendegeneration |0 (DE-588)4300182-8 |2 gnd |9 rswk-swf |
655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
689 | 0 | 0 | |a Parkinson-Krankheit |0 (DE-588)4044683-9 |D s |
689 | 0 | 1 | |a Nervendegeneration |0 (DE-588)4300182-8 |D s |
689 | 0 | |5 DE-604 | |
700 | 1 | |a Olanow, Charles Warren |e Sonstige |4 oth | |
943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-007351277 |
Datensatz im Suchindex
_version_ | 1817718702638891008 |
---|---|
adam_text | |
any_adam_object | |
building | Verbundindex |
bvnumber | BV010984674 |
callnumber-first | R - Medicine |
callnumber-label | RC382 |
callnumber-raw | RC382 |
callnumber-search | RC382 |
callnumber-sort | RC 3382 |
callnumber-subject | RC - Internal Medicine |
classification_rvk | YG 5500 |
ctrlnum | (OCoLC)35019408 (DE-599)BVBBV010984674 |
dewey-full | 616.833 |
dewey-hundreds | 600 - Technology (Applied sciences) |
dewey-ones | 616 - Diseases |
dewey-raw | 616.833 |
dewey-search | 616.833 |
dewey-sort | 3616.833 |
dewey-tens | 610 - Medicine and health |
discipline | Medizin |
format | Book |
fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000 c 4500</leader><controlfield tag="001">BV010984674</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20010108</controlfield><controlfield tag="007">t|</controlfield><controlfield tag="008">961002s1996 xx ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0125254458</subfield><subfield code="9">0-12-525445-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)35019408</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV010984674</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-20</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-578</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC382</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.833</subfield><subfield code="2">20</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YG 5500</subfield><subfield code="0">(DE-625)153506:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Neurodegeneration and neuroprotection in Parkinson's disease</subfield><subfield code="c">ed. by C. W. Olanow ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">London [u.a.]</subfield><subfield code="b">Acad. Press</subfield><subfield code="c">1996</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XII, 224 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Neuroscience perspectives</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">Parkinson's disease (PD) is an age-related neurodegenerative disorder characterized by a relatively selective degeneration of dopaminergic neurons, a loss of striatal dopamine, and intracellular inclusions. Current treatment consists of a dopamine replacement strategy, primarily using the dopamine precursor levodopa. However the majority of patients experience intolerable drug-related side effects, an unacceptable level of disability, and an increased mortality rate. Accordingly, there has been intense interest in the development of a 'neuroprotective therapy' that can prevent neuronal degeneration and slow or stop disease progression. It is likely that a cascade of events involving free radicals and oxidative stress, mitochondrial dysfunction with a bioenergetic impairment, excitotoxicity, and a rise in intracytoplasmic free calcium with activation of biodestructive enzymes contributes to the neurodegenerative process</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">There is also interest in the role of apoptotic cell death in neurodegeneration and the possibility that some small molecules can provide neuroprotection or neuronal rescue by upregulating cellular defenses through the induction of translational changes and new protein synthesis. This is the first book to comprehensive review the factors implicated in the pathogenesis of cell death in PD. Each chapter of this book examines a different factor and considers the evidence supporting its participation in the neurodegenerative process and specific strategies based on this mechanism that might lead to neuroprotection</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Zenuwstelselaandoeningen</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ziekte van Parkinson</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cell Death</subfield><subfield code="x">physiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nerve Degeneration</subfield><subfield code="x">physiopathology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nervous system</subfield><subfield code="x">Degeneration</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oxidative Stress</subfield><subfield code="x">physiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Parkinson Disease</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Parkinson Disease</subfield><subfield code="x">physiopathology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Parkinson's disease</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Parkinson-Krankheit</subfield><subfield code="0">(DE-588)4044683-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Nervendegeneration</subfield><subfield code="0">(DE-588)4300182-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Parkinson-Krankheit</subfield><subfield code="0">(DE-588)4044683-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Nervendegeneration</subfield><subfield code="0">(DE-588)4300182-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Olanow, Charles Warren</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-007351277</subfield></datafield></record></collection> |
genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
genre_facet | Aufsatzsammlung |
id | DE-604.BV010984674 |
illustrated | Illustrated |
indexdate | 2024-12-06T19:00:39Z |
institution | BVB |
isbn | 0125254458 |
language | English |
oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-007351277 |
oclc_num | 35019408 |
open_access_boolean | |
owner | DE-20 DE-355 DE-BY-UBR DE-578 |
owner_facet | DE-20 DE-355 DE-BY-UBR DE-578 |
physical | XII, 224 S. Ill., graph. Darst. |
publishDate | 1996 |
publishDateSearch | 1996 |
publishDateSort | 1996 |
publisher | Acad. Press |
record_format | marc |
series2 | Neuroscience perspectives |
spelling | Neurodegeneration and neuroprotection in Parkinson's disease ed. by C. W. Olanow ... London [u.a.] Acad. Press 1996 XII, 224 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Neuroscience perspectives Parkinson's disease (PD) is an age-related neurodegenerative disorder characterized by a relatively selective degeneration of dopaminergic neurons, a loss of striatal dopamine, and intracellular inclusions. Current treatment consists of a dopamine replacement strategy, primarily using the dopamine precursor levodopa. However the majority of patients experience intolerable drug-related side effects, an unacceptable level of disability, and an increased mortality rate. Accordingly, there has been intense interest in the development of a 'neuroprotective therapy' that can prevent neuronal degeneration and slow or stop disease progression. It is likely that a cascade of events involving free radicals and oxidative stress, mitochondrial dysfunction with a bioenergetic impairment, excitotoxicity, and a rise in intracytoplasmic free calcium with activation of biodestructive enzymes contributes to the neurodegenerative process There is also interest in the role of apoptotic cell death in neurodegeneration and the possibility that some small molecules can provide neuroprotection or neuronal rescue by upregulating cellular defenses through the induction of translational changes and new protein synthesis. This is the first book to comprehensive review the factors implicated in the pathogenesis of cell death in PD. Each chapter of this book examines a different factor and considers the evidence supporting its participation in the neurodegenerative process and specific strategies based on this mechanism that might lead to neuroprotection Zenuwstelselaandoeningen gtt Ziekte van Parkinson gtt Cell Death physiology Nerve Degeneration physiopathology Nervous system Degeneration Oxidative Stress physiology Parkinson Disease drug therapy Parkinson Disease physiopathology Parkinson's disease Parkinson-Krankheit (DE-588)4044683-9 gnd rswk-swf Nervendegeneration (DE-588)4300182-8 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Parkinson-Krankheit (DE-588)4044683-9 s Nervendegeneration (DE-588)4300182-8 s DE-604 Olanow, Charles Warren Sonstige oth |
spellingShingle | Neurodegeneration and neuroprotection in Parkinson's disease Zenuwstelselaandoeningen gtt Ziekte van Parkinson gtt Cell Death physiology Nerve Degeneration physiopathology Nervous system Degeneration Oxidative Stress physiology Parkinson Disease drug therapy Parkinson Disease physiopathology Parkinson's disease Parkinson-Krankheit (DE-588)4044683-9 gnd Nervendegeneration (DE-588)4300182-8 gnd |
subject_GND | (DE-588)4044683-9 (DE-588)4300182-8 (DE-588)4143413-4 |
title | Neurodegeneration and neuroprotection in Parkinson's disease |
title_auth | Neurodegeneration and neuroprotection in Parkinson's disease |
title_exact_search | Neurodegeneration and neuroprotection in Parkinson's disease |
title_full | Neurodegeneration and neuroprotection in Parkinson's disease ed. by C. W. Olanow ... |
title_fullStr | Neurodegeneration and neuroprotection in Parkinson's disease ed. by C. W. Olanow ... |
title_full_unstemmed | Neurodegeneration and neuroprotection in Parkinson's disease ed. by C. W. Olanow ... |
title_short | Neurodegeneration and neuroprotection in Parkinson's disease |
title_sort | neurodegeneration and neuroprotection in parkinson s disease |
topic | Zenuwstelselaandoeningen gtt Ziekte van Parkinson gtt Cell Death physiology Nerve Degeneration physiopathology Nervous system Degeneration Oxidative Stress physiology Parkinson Disease drug therapy Parkinson Disease physiopathology Parkinson's disease Parkinson-Krankheit (DE-588)4044683-9 gnd Nervendegeneration (DE-588)4300182-8 gnd |
topic_facet | Zenuwstelselaandoeningen Ziekte van Parkinson Cell Death physiology Nerve Degeneration physiopathology Nervous system Degeneration Oxidative Stress physiology Parkinson Disease drug therapy Parkinson Disease physiopathology Parkinson's disease Parkinson-Krankheit Nervendegeneration Aufsatzsammlung |
work_keys_str_mv | AT olanowcharleswarren neurodegenerationandneuroprotectioninparkinsonsdisease |